Skip to content

A Feasibility Study With a Novel, Dynamic and Disposable Over-the-counter Device for Stress Urinary Incontinence

A Feasibility, Short-term Study With a Novel, Dynamic, and Disposable Over the Counter Device for Stress Urinary Incontinence

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04325477
Enrollment
26
Registered
2020-03-27
Start date
2017-10-31
Completion date
2018-10-30
Last updated
2020-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress Urinary Incontinence

Keywords

intravaginal device, pad weight gain, stress urinary incontinence

Brief summary

This study was designed as an open label, feasibility, single-center, cross-over prospective study in women with stress urinary incontinence. Subjects served as their own control.

Detailed description

The primary objectives of this feasibility study were to evaluate the short-term efficacy of the Nolix device by measuring a reduction of SUI following a modified 1-hour PWG test and to measure the safety of the Nolix device based on adverse events that were reported by subjects during the study. The secondary objective was to assess usability and patient satisfaction using the Nolix device.

Interventions

The Nolix device is a single use, dynamic, and soft flexible intra-vaginal device for temporary management of SUI

Sponsors

Gynamics LTD
Lead SponsorINDUSTRY

Study design

Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

A prospective one-arm study with subjects serving as their own control.

Eligibility

Sex/Gender
FEMALE
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Females aged 21 and above * Suffering from Stress Urinary Incontinence * Women who can understand the nature of the study, are physically able to perform all required tasks and consent to it by signing a written Informed Consent Form prior to participation in the study

Exclusion criteria

* Age ≤ 21 years * Pregnant or planning to become pregnant during the study. * Vaginal birth or Cesarean section for the last 3 months prior to entering the study. * Severely atrophic vagina. * A history of Toxic Shock Syndrome (TSS). * Active urinary tract or vaginal infection. * Patients prone to recurrent vaginal or urinary tract infections (i.e. more than 3 times in the past year). * Has experienced unusual or unexpected vaginal bleeding within the last 6 months. * Vaginal surgery within the last 3 months prior to entering the study. * Has experienced difficulties with the use of intra-vaginal devices, including tampons. * Presence of any condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. * Average daily PWG as measured in the baseline pad period is less than 4 grams /12 hours.

Design outcomes

Primary

MeasureTime frameDescription
Continuous percent change in urine leakagePads were measured before and immediately after the 1 hour PWG testContinuous percent change in urine leakage is defined as: 100%\*(PWG without Nolix - PWG with Nolix)/PWG without Nolix.
Change in the dryness of the padPads were measured before and immediately after the 1 hour PWGSuccess (1) if following the 1-hour PWG test, the pad weight increases by no more than 1 gram or Failure (0) if following the 1-hour test, the pad weight increased by more than 1 gram.
Dichotomous change in urine leakagePads were measured before and immediately after the 1 hour PWGIn accordance with FDA recommendations, the clinically meaningful level of improvement in PWG is at least 50%. Therefore, the dichotomous change is defined for each patient as follows: Success (1), if continuous percent change in PWG \> 50% or Failure (0), if continuous percent change in PWG \< 50%

Secondary

MeasureTime frameDescription
Comfort during Nolix use1 DayComfort during Nolix device use will be measured through the Satisfaction Questionnaire, using a 10-point scale (where 1 is the most negative response and 10 the most positive, during the use of the device). Comfort during Nolix device use will be measured through the Benefit, Satisfaction, and Willingness to Continue Questionnaire, using a 10-point scale (where 1 is the most negative response and 10 the most positive, during the use of the device)
Overall satisfaction: Nolix Satisfaction Questionnaire1 DayOverall Satisfaction with the use of the Nolix device, as measured using the Nolix Satisfaction Questionnaire, selecting one of the following answers: 'Completely'; 'Somewhat'; or 'Not at all' (where 'Completely' is the most positive response and 'Not at all' is the most negative response).

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026